Navigation Links
Nektar Therapeutics Reports Second Quarter 2011 Financial Results

SAN FRANCISCO, Aug. 4, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2011.

Cash, cash equivalents, and investments at June 30, 2011 were $481.8 million as compared to $315.9 million at December 31, 2010.

Revenue for the second quarter of 2011 decreased to $17.3 million as compared to $42.6 million in the second quarter of 2010.  This decrease in revenue year over year is primarily attributable to the completion as of December 31, 2010 of the amortization of the $125.0 million upfront payment received in 2009 from AstraZeneca for the NKTR-118 and NKTR-119 license agreement.  

“Nektar continued to advance our pipeline programs in the second quarter of 2011,” said Howard W. Robin, President and Chief Executive Officer of Nektar. “In June, we finalized our pivotal study design for NKTR-102 in metastatic breast cancer with the FDA. AstraZeneca’s Phase 3 KODIAC program for NKTR-118 is continuing with the first regulatory filing planned for 2013.  We completed our first clinical study of NKTR-181, our novel opioid candidate, with positive proof-of-concept results.  Finally, we are on track to introduce a new IND candidate later this year.”

Total operating costs and expenses in the second quarter of 2011 increased by 27% to $51.6 million, compared to $40.7 million in the second quarter of 2010.  This increase was primarily a result of higher development expenses related to the advancement of multiple programs in clinical development.  Research and development expense increased to $32.3 million in the second quarter of 2011 as compared to $25.6 million for the second quarter in 2010.  General and administrative expense increased to $11.2 million in the second quarter of 2011 from $10.2 million in the second quarter of 2010.

Net loss for the second quarter ended June 30, 2011 was $36.4 million or $0.32 loss per share as compared to a net loss of $0.5 million or $0.01 loss per share in the second quarter of 2010.

Nektar also announced several upcoming data presentations for NKTR-102 and NKTR-181:

Phase 2 data for NKTR-102 in metastatic breast cancer will be presented in an oral session at the 2011 ASCO Breast Cancer Symposium on September 9, 2011:

  • Abstract #269: “Final results of NKTR-102, a topoisomerase I inhibitor-polymer conjugate, in patients (Pts) with pretreated metastatic breast cancer (MBC) demonstrating significant antitumor activity,” A. A. Garcia, et al.

  • Phase 1 data for NKTR-181 will be presented at American Academy of Pain Management (AAPM) Annual Clinical Meeting on September 21, 2011:

  • "Phase 1 Study of Oral NKTR-181, a Novel Opioid Analgesic Molecule with Reduced Abuse Potential and Favorable Safety Profile," Lynn Webster, MD, et al.
  • "NKTR-181: A Novel Mu-Opioid Agonist That Exhibits Reduced Abuse Potential and Maintains Full Analgesic Activity Following Repeat Dosing in Preclinical Rodent Models," Stephen D. Harrison, PhD, et al.

  • Conference Call to Discuss Second Quarter 2011 Financial ResultsNektar management will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT) today, Thursday, August 4, 2011.

    The press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: The web broadcast of the conference call will be available for replay through Friday, September 2, 2011.

    To access the conference call, follow these instructions:
    Dial: (877) 299-4454 (U.S.); (617) 597-5447 (international)
    Passcode: 93854703 (Nektar Therapeutics is the host)

    An audio replay will also be available shortly following the call through Friday, September 2, 2011 and can be accessed by dialing (888) 286-8010 (U.S.); or (617) 801-6888 (international) with a passcode of 53256804.

    In the event that any non-GAAP financial measure is discussed on the conference call that is not explained on the conference call, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

    About NektarNektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for NKTR-118, an investigational drug candidate, being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation.  The agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of NKTR-118 and an opioid.  NKTR-181, a novel mu-opioid analgesic molecule, is being evaluated in Phase 1 clinical studies.  In oncology, NKTR-102, a novel topoisomerase I-inhibitor, is being evaluated in Phase 2 clinical studies for the treatment of breast, ovarian and colorectal cancers.  

    Nektar's technology has enabled seven approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.

    Nektar is headquartered in San Francisco, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at

    This press release contains forward-looking statements that reflect management's current views regarding the value and potential of Nektar's drug candidate pipeline, the value and potential of Nektar's technology platform, the timing of the commencement of clinical trials and regulatory submissions, and the value and potential of certain of Nektar's collaborations with third parties.  These forward-looking statements involve numerous risks and uncertainties, including but not limited to: (i) Nektar's product candidates and those of its collaboration partners are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval for numerous reasons including safety and efficacy findings even after positive findings in preclinical and clinical studies; (ii) the timing of the commencement or end of clinical trials (and related regulatory submissions) and the successful commercial launch of our drug candidates may be delayed or unsuccessful due to slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, regulatory delay, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (iii) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of Nektar's technology platform to potential new drug candidates is therefore highly uncertain and unpredictable and one or more research and development programs could fail; (iv) Nektar's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required in the future; (v) the outcome of any intellectual property or other litigation related to Nektar's proprietary product candidates or complex commercial agreements; and (vi) certain other important risks and uncertainties set forth in Nektar's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on April 29, 2011 and the Current Report on Form 8-K filed today.  Actual results could differ materially from the forward-looking statements contained in this press release.  Nektar undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise.Nektar Investor Inquiries:Jennifer Ruddock/Nektar Therapeutics

    (415) 482-5585Susan Noonan/SA Noonan Communications, LLC

    (212) 966-3650Nektar Media Inquiries:Karen Bergman/BCC Partners

    (650) 575-1509 Michelle Corral/BCC Partners

    (415) 794-8662NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED BALANCE SHEETS(In thousands)(Unaudited)ASSETSJune 30, 2011December 31, 2010

    (1)Current assets:Cash and cash equivalents$
    7,755Short-term investments351,280298,177Accounts receivable8,46025,102Inventory9,7977,266Other current assets7,9325,679Total current assets389,095353,979Long-term investments118,941-Property and equipment, net85,38189,773Goodwill76,50176,501Other assets936972Total assets$
    521,225LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable$
    7,194Accrued compensation9,4359,252Accrued expenses8,1298,540Accrued clinical trial expenses13,83212,144Deferred revenue, current portion19,86720,584Other current liabilities6,7686,394Total current liabilities61,27464,108Convertible subordinated notes214,955214,955Capital lease obligations15,86317,014Deferred revenue117,931124,763Deferred gain3,7154,152Other long-term liabilities5,8405,571Total liabilities419,578430,563Commitments and contingenciesStockholders' equity:Preferred stock--Common stock119Capital in excess of par value1,587,4611,354,232Accumulated other comprehensive income766968Accumulated deficit(1,336,962)(1,264,547)Total stockholders' equity251,27690,662Total liabilities and stockholders' equity$
    521,225(1) The consolidated balance sheet at December 31, 2010 has been derived from the audited financial statements at that date but does not include all of the information and notes required by generally accepted accounting principles in the United States for complete financial statements. NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share information)(Unaudited)Three Months EndedSix Months EndedJune 30, June 30,2011201020112010Revenue:Product sales and royalties

    $  11,008$ 11,154$  15,801$ 14,738License, collaboration and other

    6,32331,40912,82961,062Total revenue

    17,33142,56328,63075,800Operating costs and expenses:Cost of goods sold

    8,1404,88911,4039,185Research and development

    32,27025,60062,44648,886General and administrative

    11,18510,20722,91219,220Total operating costs and expenses

    51,59540,69696,76177,291Income (loss) from operations

    (34,264)1,867(68,131)(1,491)Non-operating income (expense):Interest income

    529393961856Interest expense

    (2,570)(2,909)(5,155)(5,860)Other income (expense), net

    (16)163118187Total non-operating expense

    (2,057)(2,353)(4,076)(4,817)Loss before provision for income taxes

    (36,321)(486)(72,207)(6,308)Provision for income taxes

    6031208339Net loss

    $ (36,381)$
    (517)$ (72,415)$ (6,647)Basic and diluted net loss per share

    (0.32)$   (0.01)$
    (0.65)$   (0.07)Shares used in computing basic anddiluted net loss per share

    114,15394,065111,43093,849NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(In thousands)(Unaudited)Six Months Ended June 30,20112010Cash flows from operating activities:Net loss

    $   (72,415)$   (6,647)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization

    7,6498,334Stock-based compensation

    9,6828,105Other non-cash transactions

    620(205)Changes in operating assets and liabilities:Accounts receivable


    (2,531)(3,306)Other assets

    (2,191)(136)Accounts payable

    (3,149)2,183Accrued compensation

    183(2,144)Accrued expenses

    2,3711,012Accrued clinical trial expenses

    1,688(818)Deferred revenue

    (7,549)(55,120)Other liabilities

    (658)(729)Net cash used in operating activities

    $   (49,658)$ (54,116)Cash flows from investing activities:Purchases of investments

    (509,681)(218,275)Sales of investments

    180,4788,197Maturities of investments

    156,962241,256Purchases of property and equipment

    (6,845)(8,796)Net cash (used in) provided by investing activities

    $ (179,086)$  22,382Cash flows from financing activities:Payments of loan and capital lease obligations

    (934)(731)Proceeds from issuances of common stock

    223,5496,148Net cash provided by financing activities

    $  222,615$
    5,417Effect of exchange rates on cash and cash equivalents

    -(36)Net decrease in cash and cash equivalents

    (6,129)$ (26,353)Cash and cash equivalents at beginning of period

    17,75549,597Cash and cash equivalents at end of period

    ,626$  23,244

    SOURCE Nektar Therapeutics
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Nektar to Announce Financial Results for the Second Quarter of 2011 on Thursday, August 4, 2011, After Close of U.S.-Based Financial Markets
    2. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2011 Global Healthcare Conference in New York
    3. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
    4. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
    5. Nektar to Announce Financial Results for the First Quarter of 2011 on Wednesday, April 27, 2011, After Close of U.S.-Based Financial Markets
    6. Nektar Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results
    7. Nektar Therapeutics President and CEO Howard W. Robin to Present at the 31st Annual Cowen and Company Healthcare Conference in Boston
    8. Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2010 on Tuesday, March 1, 2011, After Close of U.S.-Based Financial Markets
    9. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
    10. Nektar Therapeutics Reports Third Quarter 2010 Financial Results
    11. Nektar to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets
    Post Your Comments:
    (Date:11/25/2015)... , November 25, 2015 Kitov ... ) (TASE: KTOV), a biopharmaceutical company focused on the ... various clinical conditions, today announced the closing of its ... Shares ( ADSs ), each representing 20 ordinary shares ... 3,158,900 ADSs. The ADSs and warrants were issued in ...
    (Date:11/25/2015)... , Nov. 25, 2015 Allergan ... pharmaceutical company, and Rugen Therapeutics, a start-up  biotechnology ... for unmet CNS disorders and funded by the ... they have entered into an exclusive collaboration to ... for Autism Spectrum Disorders (ASD) and Obsessive Compulsive ...
    (Date:11/25/2015)... Israel , November 25, 2015 ... "New Investors"), pursuant to which BioLight and the New ... IOPtima Ltd. subsidiary ("IOPtima") via a private placement. The ... of its innovative IOPtimate™ system used in the treatment ... approval pathway process for the IOPtimate™ system with the ...
    Breaking Medicine Technology:
    (Date:11/25/2015)... ... ... “While riding the bus, I saw a passenger in a wheelchair drenched from ... a convenient and comfortable way to protect them from bad weather, so I invented ... during cold or inclement weather. In doing so, it ensures that the user remains ...
    (Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
    (Date:11/25/2015)... ... November 25, 2015 , ... An unlikely combination ... in a way for homeless people to have a more dignified and comfortable ... initiative whereby they are repurposing plastic bags into sleeping mats for the homeless. ...
    (Date:11/25/2015)... ... November 25, 2015 , ... ... focused on providing comprehensive solutions involving adult stem cell therapies to patients with ... deemed the “Regenestem” name as a Registered Trademark (RTM). , Organizations are required ...
    (Date:11/24/2015)... ... 2015 , ... Genesis Chiropractic Software helps practice owners automate ... between the practice owner and the patient that automatically manages all five aspects ... Click here to learn more. , According to Dr. Brian ...
    Breaking Medicine News(10 mins):